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xxxBACKGROUND The currently recommended duration of dual antiplatelet therapy (DAPT) in drug-eluting stent
(DES) recipients is 12 months to reduce the risk of late stent thrombosis, particularly in those with acute coronary
syndrome (ACS).
OBJECTIVES This study hypothesized that antiplatelet treatment with DAPT for 6 months may be noninferior to
24-month DAPT in aspirin-sensitive patients.
METHODS A multicenter, randomized study assigned patients undergoing implantation of everolimus-eluting stents
with conﬁrmed nonresistance to aspirin to receive 6- or 24-month DAPT. The primary endpoint was a composite of death,
myocardial infarction, urgent target vessel revascularization, stroke, and major bleeding at 12 months post-stenting.
RESULTS A total of 2,031 patients were enrolled in 70 European and Middle Eastern centers. The trial was prematurely
terminated due to recruitment problems, leaving 941 patients randomized to 24-month DAPT and 953 to 6-month DAPT.
The 2 treatment groups had similar baseline and procedural characteristics. There was no signiﬁcant difference in the
primary endpoint (24-month: 1.5% vs. 6-month: 1.6%; p ¼ 0.85). Noninferiority was demonstrated for 6- versus
24-month DAPT, with an absolute risk difference of 0.11% (95% conﬁdence interval: 1.04% to 1.26%; p for
noninferiority ¼ 0.0002). There were no signiﬁcant differences in stent thrombosis or bleeding complications. In the 792
(44%) high-risk patients with ACS, primary and secondary endpoints did not signiﬁcantly differ (hazard ratio: 1.7 [95%
conﬁdence interval: 0.519 to 6.057; p ¼ 0.361]).
CONCLUSIONS Rates of bleeding and thrombotic events were not signiﬁcantly different according to 6- versus
24-month DAPT after PCI with new-generation DES in good aspirin responders. (Is There A LIfe for DES After Discon-
tinuation of Clopidogrel [ITALICplus]; NCT01476020) (J Am Coll Cardiol 2015;65:777–86) © 2015 by the American
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MI = myocardial infarction
PCI = percutaneous coronary
intervention
TVR = target vessel
revascularization
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778R andomized trials have demonstratedthat coronary drug-eluting stents(DES) reduce angiographic resteno-
sis and emergency target vessel revasculari-
zation (TVR) compared with bare-metal
stents (BMS) (1–4). However, concerns have
been generated by trials showing an
increased propensity for late and very late
stent thrombosis (ST) in ﬁrst-generation
DES compared with BMS (5–7).SEE PAGE 787Second-generation DES show improved
efﬁcacy and safety, with several studiesreporting signiﬁcant decreases in mortality and
myocardial infarction (MI) (8–13) compared with ﬁrst-
generation DES and BMS. Speciﬁcally, the risk of
deﬁnite or probable ST is on average 50% lower with
newer-generation DES versus ﬁrst-generation stents
(10–13).
Several randomized and observational trials of
these newer DES suggest that they permit a shorter
duration of dual antiplatelet therapy (DAPT) (14–20).
Current guidelines recommend 6 months of DAPT
post-DES in stable patients (21) and 1 year of DAPT in
patients with acute coronary syndrome (ACS) (21,22).
However, when our trial began, the guidelines (22)
recommended 12 months of DAPT regardless of the
clinical situation. A randomized, multicenter trial
was, therefore, initiated to assess the effect of 6
versus 24 months of DAPT on medium-term clinical
outcomes after coronary intervention in a real-world
clinical population receiving second-generation DES.
To be sure that patients would be protected by their
antiplatelet therapy, patients resistant to aspirin were
excluded (23,24).
METHODS
STUDY DESIGN AND PATIENTS. The ITALIC (Is There
A LIfe for DES after Discontinuation of Clopidogrel)
trial was a prospective, open-label randomized triale, Rouen, France; ###Clinique Saint Augustin, Bordeaux, France;
Hospitalier, Compiègne, France; zzzzPolyclinique de Bois, Ber
rance; kkkkCentre Hospitalier, Vannes, France; {{{{Centre Hosp
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received October 18, 2014; revised manuscript received Novembconducted at 70 sites in Europe and the Middle
East. Patients were included in 48 French sites from
November 2008 to December 2010 (ITALIC, conducted
by the French Society of Cardiology) and in 7 Euro-
pean and Middle East sites from January 2012 to
November2013under thesameprotocol (ITALICPLUS).
Complete lists and detailed information regarding the
institutions involved are given in theOnlineAppendix.
The study was undertaken according to the Declara-
tion of Helsinki, and the national review board of
each participating center approved the trial protocol.
Inclusion criteria were: patients age 18 years or
older; eligible for percutaneous coronary intervention
(PCI); implanted with at least 1 Xience V DES (Abbott
Vascular Devices, Santa Clara, California); and all
clinical situations excluding primary PCI for acute MI
and treatment of the left main artery. Only treatment
with Xience V was permitted. All patients gave written
informed and dated consent to the study. Patients
were not pre-treated with abciximab during their
hospital stay.When the studywas designed, resistance
to aspirin was suspected to be associated with ST
after DAPT discontinuation. Aspirin resistance was
checked, and nonresponders were excluded from ran-
domization. In patients who received tiroﬁban or
eptiﬁbatide, aspirin resistance was checked at least 24
h after the last injection. Patientswere pre-treatedwith
aspirin and clopidogrel (or prasugrel or ticagrelor)
pre-PCI. Exclusion criteria were: prior DES implanta-
tion within 1 year; known platelet level<100,000/ml or
known hemorrhagic diathesis; oral anticoagulation
therapy or abciximab treatment during hospital stay;
contraindications to aspirin or clopidogrel (prasugrel
or ticagrelor); major surgery within the preceding
6 weeks; evidence of active gastrointestinal or uro-
genital bleeding; severe liver failure; any surgery
scheduled during the year after enrollment; or severe
concomitant disease with <2 years’ life expectancy.
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779clopidogrel 75 mg/day (or prasugrel 60 mg/day, or
ticagrelor 90 mg twice per day). Aspirin resistance
was assessed after an initial dose of 75 mg. Patients
responding poorly to the ﬁrst aspirin dose were either
considered resistant or underwent a second check
after 2 days of 160 mg oral aspirin; a third check was
made after 2 days of 325 mg oral aspirin in case of
poor response to 160 mg, and this dose was applied
throughout the trial. If poor response persisted after
increasing the aspirin dose, patients were included in
the aspirin-resistant control group, with the same
follow-up. During PCI hospitalization, patients sen-
sitive to aspirin were assigned in a 1:1 ratio to 6 versus
24 months of DAPT by centralized randomization
using an interactive web-based system. If an end-
point (see the following text) occurred during the ﬁrst
6 months, the patient was withdrawn from analysis. It
was a full analysis set.
Three aspirin resistance tests were used: PFA-100
(Dade-Behring, Deerﬁeld, Illinois), deﬁning aspirin
response as an epinephrine-collagen cartridge closure
time >165 s; multiplate electrical impedance aggreg-
ometry (Dynabyte, Munich, Germany), deﬁning as-
pirin response as a $30% reduction in platelet
aggregation; or VerifyNow Aspirin (Accumetrics, San
Diego, California), deﬁning aspirin response as $550
aspirin reaction units (25). The test used depended on
the center; however, the same test was systematically
used in any given patient.
ENDPOINTS. The primary endpoint was a composite
of death, MI, repeat emergency TVR, stroke, or major
bleeding according to the Thrombolysis In Myocardial
Infarction (TIMI) criteria (26), from all causes, within
12 months of stenting. All clinical endpoints were
deﬁned according to the Academic Research Con-
sortium criteria (27,28).
MI was classiﬁed as Q-wave or non–Q-wave MI.
Q-wave MI was deﬁned by recurrence of symptoms
and/or development of new pathological Q waves in
2 or more contiguous leads with elevated creatine
kinase (CK), CK-MB, or troponin levels. Non–Q-wave
MI was deﬁned by >2-fold CK elevation with elevated
CK-MB or troponin without new pathological Q waves.
Emergency TVR was deﬁned as emergency repeat
coronary revascularization (PCI or surgery) of any
segment of the treated coronary artery within 12
months of stenting. Stroke was deﬁned as acute new
neurological deﬁcit ending in death or lasting longer
than 24 h, diagnosed as stroke by a physician; stroke
was classiﬁed as hemorrhagic (on computed tomog-
raphy, cardiac magnetic resonance imaging, or au-
topsy) or nonhemorrhagic. Major bleedingwas deﬁned
according to the TIMI classiﬁcation as intracranialhemorrhage, 5 g/dl decrease in hemoglobin concen-
tration, or 15% absolute decrease in hematocrit.
Secondary endpoints were incidence of the same
composite endpoint at 24 and 36 months as well as all
individual endpoints used in the composite major
adverse coronary event score (death, MI, or repeat
emergency TVR and stroke requiring readmission). In
addition, the incidence of minor and minimal
bleeding complications at 12, 24, and 36 months was
assessed according to the TIMI classiﬁcation (26). All
composite endpoints are presented with the individ-
ual components in hierarchical order.
DATA MANAGEMENT. In-hospital adverse events
were recorded before discharge. Six-, 12-, 24-, and
36-month clinical follow-up data were obtained in
outpatient consultation. Clinical data were processed
by an independent external contract research orga-
nization (CERC, Massy, France). Adverse clinical
events were independently adjudicated by an ex-
ternal clinical event committee. To ensure high data
quality, all clinical sites were monitored at least once
per year (all adverse events, endpoint-related events,
and 15% random patient ﬁles); all source documents
concerning events were provided to the clinical event
committee, for accuracy and completeness. For the
aspirin-resistant group, only patients with serious
adverse events were fully monitored, with an addi-
tional 10% random spot-check of remaining data.
STATISTICAL ANALYSIS. In the SPIRIT V (A Clinical
Evaluation of the XIENCE V Everolimus-Eluting Coro-
nary Stent System in the Treatment of Patients With
De Novo Coronary Artery Lesions) study (29), the
composite rate of cardiac death, MI (per protocol), ST
(deﬁnite/probable), major bleeding (TIMI), and stroke
between 6-month and 1-year follow-up was estimated
to be less than but close to 2%. Sample size was calcu-
lated to detect noninferiority of short compared to
long-term DAPT, with 80% power. The expected rate
of events was 3%, and the noninferiority margin was
set at 2%, leading to inclusion of 900 patients/arm,
for a type I error of alpha ¼ 5%. With a drop-out rate
of 20% in the test group and 5% in the control group,
and considering a 10% rate of aspirin resistance, a
total of 2,475 patients needed to be included to enable
a conclusion to be drawn. Sample size was calculated
considering an alpha ¼ 5%, but to be compliant with
the most recent guidelines, the noninferiority conﬁ-
dence interval (CI) has beenperformedﬁnally at 97.5%.
Statistical comparison was performed between the
6- and 24-month DAPT groups; the aspirin resistance
group results were only descriptive. Baseline charac-
teristics were compared between the 2 treatment
groups by Student t test or Wilcoxon rank sum test as
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780appropriate for continuous variables, and chi-square
test for categorical variables. Kaplan-Meier survival
curves were constructed (30), and differences
between the curves were tested by the log-rank test.
Proportional hazard models (31) were used to esti-
mate hazard ratios (HRs) and 95% CIs. Survival
analysis was performed in the intention-to-treat
population, with the primary endpoint as the event.
Sensitivity analysis was performed in the per-
protocol population to assess robustness of results.
Statistical analyses were performed and validated
using SAS version 9.4 software (SAS Institute Inc.,
Cary, North Carolina). Noninferiority was tested on
the primary endpoint with a 1-tailed 97.5% CI. Times
to primary endpoint and all secondary endpoints
were also assessed on survival analysis. The group of
patients with ACS was analyzed post hoc.FIGURE 1 Study Flow Chart
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DES ¼ drug-eluting stent(s); MI ¼ myocardial infarction; TVR ¼ target vRESULTS
STUDY POPULATION. Figure 1 shows the trial ﬂow
chart with 2,031 patients enrolled. The trial was pre-
maturely terminated due to recruitment problems.
After aspirin monitoring, 131 patients were classiﬁed
as aspirin resistant, and were not randomized but
were followed up as the aspirin-resistant group.
A total of 1,894 patients were eligible for randomi-
zation. Before 6 months, 44 patients were excluded
from analysis due to an endpoint-related event
(13 deaths, 10 MIs, and 2 TVRs). Thus, 1,850 patients
were randomized to 24-month DAPT (n ¼ 924) versus
6-month DAPT (n ¼ 926).
The 2 test groups had similar baseline (Table 1) and
procedural (Table 2) characteristics. One-third of the
patients had a history of type 2 diabetes; one-fourthGroup 2:
Dual oral antiplatelet regimen
for 6 months followed by
aspirin alone
n=926
imen
 by
912 patients analyzed
on primary endpoint
(1-Year)
d aspirin responders
Randomization
n=1,894
ndomization applied
nts during first 6 months
n=1,850
44 patients not randomized
Death = 13
MI = 10
TVR = 2
Other = 19 (7 with no consent validated)
Xience DES
istant and 44 were excluded due to an endpoint-related event. The
us 6-month DAPT (n ¼ 926). DAPT ¼ dual antiplatelet therapy;
essel revascularization.
TABLE 1 Baseline Patient Characteristics
Resistant
Group
(n ¼ 131)
24-Month
DAPT
(n ¼ 910)
6-Month
DAPT
(n ¼ 912) p Value
Age, yrs 62.6  10.8 61.5  11.1 61.7  10.9 0.792
Male 106 (80.9) 721 (79.2) 737 (80.8) 0.399
Body mass index,
kg/m2
27.5  4.2 27.1  4.7 27.0  4.6 0.549
Type 2 diabetes 42 (32.1) 344 (37.8) 331 (36.3) 0.505
Hypertension 76 (58.0) 589 (64.7) 595 (65.2) 0.817
Hyperlipidemia 84 (64.1) 611 (67.1) 612 (67.1) 0.986
Smoker 69 (52.7) 480 (52.7) 464 (50.9) 0.424
Heredity 50 (38.2) 325 (35.7) 322 (35.3) 0.856
Previous MI 36 (27.5) 134 (14.7) 142 (15.6) 0.615
Previous PCI 39 (29.8) 205 (22.5) 220 (24.1) 0.421
Previous CABG 6 (4.6) 45 (4.9) 61 (6.7) 0.111
Previous stroke 6 (4.6) 26 (2.9) 25 (2.7) 0.881
Renal insufﬁciency 4 (3.1) 25 (2.7) 28 (3.1) 0.682
Ejection fraction 0.321
<31% 1 (0.8) 20 (2.2) 29 (3.2)
31%–50% 21 (16.0) 151 (16.6) 162 (17.8)
>50% 65 (49.6) 514 (56.5) 482 (52.9)
Unknown 44 (33.6) 225 (24.7) 239 (26.2)
Clinical presentation 0.911
Stable angina 53 (40.5) 378 (41.5) 375 (41.1)
Silent ischemia 18 (13.7) 183 (20.1) 185 (20.3)
Unstable angina 23 (17.6) 149 (16.4) 143 (15.7)
NSTEMI 9 (6.9) 65 (7.1) 67 (7.3)
STEMI 0 3 (0.3) 1 (0.1)
Antiplatelet therapy
associated
Clopidogrel 129 (98.5) 895 (98.4) 902 (98.9)
Prasugrel 2 (1.5) 16 (1.8) 15 (1.6)
Ticagrelor 0 0 1 (0.1)
Values are mean  SD or n (%).
CABG ¼ coronary artery bypass graft; DAPT ¼ dual antiplatelet therapy;
MI ¼ myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial
infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment
elevation myocardial infarction.
TABLE 2 Procedural Characteristics
Resistant Group
(n ¼ 131)
24-Month DAPT
(n ¼ 910)
6-Month DAPT
(n ¼ 912) p Value
Procedural success 130 (99.2) 901 (99.0) 895 (98.1) 0.112
Target lesion coronary artery
Left main 4 (3.1) 8 (0.9) 14 (1.5) 0.197
Left anterior descending 96 (73.3) 658 (72.3) 669 (73.4) 0.615
Left circumﬂex 59 (45.0) 436 (47.9) 456 (50.0) 0.373
Right coronary artery 62 (47.3) 474 (52.1) 489 (53.6) 0.513
Bypass graft 5 (3.8) 39 (4.3) 59 (6.5) 0.038
Total lesions treated/patient 0.239
1 77 (58.8) 494 (54.3) 459 (50.3)
2 38 (29.0) 252 (27.7) 275 (30.2)
$3 16 (12.2) 164 (18.0) 178 (19.5)
Number of Xience V stents
per patient
1.6  0.8 1.7  1.0 1.7  1.0 0.497
Total stent length, mm 33.2  22.7 37.8  26.1 38.6  25.6 0.533
Stent diameter, mm 3.0  0.2 3.1  0.3 3.1  0.3 0.113
Rotablator 4 (2.9) 12 (1.3) 15  1.6) 0.553
At least 1 restenotic lesion 5 (3.8) 51 (5.6) 54 (5.9) 0.772
Values are n (%) or mean  SD.
DAPT ¼ dual antiplatelet therapy.
TABLE 3 1-Year Clinical Outcomes in the Intention-to-Treat Study Population
Resistant
Group
(n ¼ 131)
24-Month
DAPT
(n ¼ 910)
6-Month
DAPT
(n ¼ 912)
Hazard Ratio
(95% CI) p Value
Primary endpoint: death
from any cause, MI,
stroke, TVR, or
major bleeding
2 (1.5) 14 (1.5) 15 (1.6) 1.072 (0.517–2.221) 0.85
Secondary endpoints
Minor bleeding 0 4 (0.4) 5 (0.5) 1.247 (0.335–4.643) 0.74
Minimal bleeding 1 (0.8) 6 (0.7) 6 (0.7) 0.997 (0.321–3.090) 0.99
Death
All deaths 1 (0.8) 7 (0.8) 8 (0.9) 1.143 (0.414–3.152) 0.80
Cardiac death 0 3 (0.3) 5 (0.5) 1.667 (0.398–6.974) 0.48
Myocardial infarction 0 4 (0.4) 6 (0.7) 1.500 (0.423–5.317) 0.53
Stroke 0 4 (0.4) 0 N/A
TVR 1 (0.8) 2 (0.2) 5 (0.5) 2.499 (0.485–12.882) 0.27
Stent thrombosis 0 0 3 (0.3) N/A
Major bleeding 0 3 (0.3) 0 N/A
Values are n (%) unless otherwise indicated.
CI ¼ conﬁdence interval; TVR ¼ urgent target vessel revascularization; other abbreviations as in Table 1.
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781had previous PCI or bypass surgery; and nearly one-
half presented with ACS. In more than one-half of
the patients, 2 or more lesions were stented, with a
mean stent length of approximately 37 mm.
FOLLOW-UP AND CLINICAL OUTCOMES. The 1-year
follow-up information could be obtained for 98.5%
of patients. In the 6-month DAPT arm, 221 patients
(24.2%) did not follow the 6-month treatment dura-
tion: 83 (8.9%) continued treatment longer, and the
others stopped earlier. In the 24-month DAPT arm,
49 patients (5.4%) discontinued treatment before
24 months. Table 3 shows endpoints during 1-year
follow-up. There was no signiﬁcant difference
between treatment groups regarding the primary
endpoint (1.5% vs. 1.6%; p ¼ 0.85) (Figure 2) or its
components (secondary endpoint). The TVR rates
were very low in both groups (n ¼ 2 [0.2%] vs. n ¼ 5
[0.5%]); there were no stent thromboses in the6-month DAPT group, and only 3 in the 24-month
group. There was no signiﬁcant difference in
bleeding complications. Major bleeding occurred in
only 3 patients in the 24-month group. For minor
bleeding, the HR was 1.247 (95% CI: 0.335 to 4.643;
p ¼ 0.74). In the 792 (44%) high-risk patients with
ACS, primary and secondary endpoints did not
signiﬁcantly differ from the global treatment popu-
lation (Table 4, Central Illustration).
Noninferiority was established for 6- versus
24-month DAPT, with an absolute risk difference
FIGURE 2 Kaplan-Meier Survival Curve for Primary Endpoint
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At 12 months, there was no signiﬁcant difference in the primary endpoint between
treatment arms (24-month 1.5% vs. 6-month 1.6%, p ¼ 0.85). DAPT ¼ dual antiplatelet
therapy; M ¼ months; other abbreviations as in Figure 1.
TABLE 4 1-Year Clin
Study Population
Primary endpoint: deat
from any cause, M
stroke, TVR, or m
bleeding
Secondary endpoints
Minor bleeding
Minimal bleeding
Death
All deaths
Cardiac death
MI
Stroke
TVR
Stent thrombosis
Major bleeding
Values are n (%) unless ot
Abbreviations as in Tabl
Gilard et al. J A C C V O L . 6 5 , N O . 8 , 2 0 1 5
ITALIC: 6- Versus 24-Month DAPT M A R C H 3 , 2 0 1 5 : 7 7 7 – 8 6
782of 0.11% (95% CI: 1.04% to 1.26%; p for non-
inferiority ¼ 0.0002).
DISCUSSION
This prospective, randomized trial demonstrated
that 6-month DAPT after second-generation DES im-
plantation was noninferior to 24-month DAPT for theical Outcomes in the High-Risk ACS Intention-to-Treat
Resistant
Group
(n ¼ 50)
24-Month
DAPT
(n ¼ 397)
6-Month
DAPT
(n ¼ 395)
Hazard Ratio
(95% CI) p Value
h
I,
ajor
0 4 (1.0) 7 (1.8) 1.773 (0.519–6.057) 0.361
0 3 (0.8) 1 (0.3) 0.334 (0.035–3.211) 0.34
0 3 (0.8) 2 (0.5) 0.669 (0.112–4.002) 0.66
0 1 (0.3) 4 (1.0) 4.041 (0.452–36.151) 0.21
0 0 3 (0.8) N/A
0 2 (0.5) 2 (0.5) 1.006 (0.142–7.144) 0.99
0 1 (0.3) 0 N/A
0 0 3 (0.8) N/A 0
0 0 2 (0.5) N/A
0 1 (0.3) 0 N/A
herwise indicated.
es 1 and 3.composite primary endpoint of death, stroke, MI,
emergency TVR, and major bleeding as well as for the
secondary endpoints.
The protocol was designed assuming a major
adverse cardiac event rate w3% between 6 and
12 months in the control group; the observed rate
was in fact 1.5% and 1.6% in the 24- and 6-month
DAPT groups, respectively, which was signiﬁcantly
lower than expected. From a statistical point of view,
this difference introduced no bias, as a lower ex-
pected endpoint rate would have led to a smaller
sample. A low event rate was observed even in high-
risk patients presenting with ACS, although primary
PCI was an exclusion criterion (Table 4). A single type
of DES was implanted to minimize potential variation
in efﬁcacy and safety; the Xience V cobalt-chromium
everolimus-eluting stent used in the present trial is
probably 1 of the safest new-generation models. A
large-scale network meta-analysis including more
than 85,000 randomized patients showed it to be
safe, with better outcomes than BMS, ﬁrst-generation
DES, or certain other new-generation DES (32).
One-fourth of the patients (24.2%) allocated to the
short-DAPT arm did not respect the 6-month treat-
ment duration. However, only 83 (8.9%) of these pa-
tients continued treatment longer, whereas the vast
majority stopped early.
The present trial did not show an increase in
bleeding in the long-DAPT arm, in contrast to the
PRODIGY (Prolonging Dual Antiplatelet Treatment
After Grading Stent-Induced Intimal Hyperplasia)
trial, which also compared 6- to 24-month DAPT, but
demonstrated an increased rate of bleeding in the
long-duration arm (14).
Regardless of the type of DES, several guidelines
call for a minimum of 12 months of DAPT after DES
implantation to prevent late ST (22,33). However,
second-generation DES have been shown to have
a safety proﬁle similar to or even better than BMS
(4,11–13,34). No data support prolonging DAPT
beyond 1 year after DES implantation. Indeed, merged
data from 2 randomized stenting trials (n ¼ 2,071)
showed a nonsigniﬁcant trend for a higher rate of MI,
stroke, and death at a median of 19 months of follow-
up in patients continuing versus stopping clopidogrel
1 year after stenting (35). Several randomized trials
comparing short (3 to 6 months) versus extended
(12 to 24 months) DAPT consistently showed a lack of
beneﬁt in terms of ischemic outcome but a higher risk
of bleeding (14,16,17). A recent meta-analysis of brief
versus prolonged DAPT (>12 months) concluded that
extending DAPT beyond 6 months increased bleeding
risk without reducing the rate of ischemic events
(15,36). These ﬁndings explain the modiﬁcations
CENTRAL ILLUSTRATION 1-Year Clinical Outcomes in ACS and Non-ACS Patients
All death
Favors 6-Month DAPT Favors 24-Month DAPT
0.10.01 1 10 100
Hazard Ratio and 95% CI with p Value for DAPT ACS Interaction
Cardiac death
ACS (n = 0)
Non-ACS
Myocardial infarction
ACS
Non-ACS
TVR
ACS (n = 0)
non-ACS
Minor bleeding
ACS
Non-ACS
Minimal bleeding
ACS
Non-ACS
ACS
Non-ACS
ACS
Non-ACS
Primary endpoint
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In the overall trial population, 6-month DAPT was noninferior to 24-month treatment (p for noninferiority ¼ 0.0002), and there were no
differences in stent thrombosis or bleeding complications. These endpoints did not differ signiﬁcantly in the 792 (44%) high-risk patients with
ACS (hazard ratio: 1.7%; 95% CI: 0.519 to 6.057; p ¼ 0.361). ACS ¼ acute coronary syndrome(s); CI ¼ conﬁdence interval; DAPT ¼ dual
antiplatelet therapy. HR ¼ hazard ratio; TVR ¼ target vessel revascularization; UCL ¼ upper conﬁdence limit.
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783to current guidelines, recommending that DAPT be
administered for 6 months after new-generation DES
in stable angina but for 1 year in ACS (21). The present
trial demonstrated noninferior safety for 6- versus
24-month DAPT, without any speciﬁc safety advan-
tage in terms of bleeding with short DAPT.
The 1-year duration of DAPT after ACS in the most
recent guidelines was supported by 3 randomized
trials. In the oldest trial (conducted 15 years ago), PCI-
CURE (a substudy of the Clopidogrel in Unstable
angina to prevent Recurrent Events trial) (37), PCI was
performed with stenting in only 80% of cases, and
that was with BMS. The other trials, PLATO (PLATelet
inhibition and patient Outcomes) and TRITON-TIMI 38
(Trial to Assess Improvement in Therapeutic Out-
comes by Optimizing Platelet Inhibition with Prasu-
grel–Thrombolysis In Myocardial Infarction 38)
(38,39), used DES in only 19% and 40% of cases,
respectively; these were ﬁrst-generation DES,whereas second-generation DES have thin stent
struts, advanced polymers, and improved anti-
proliferation agents that have further improved efﬁ-
cacy and safety. Moreover, these 2 more recent trials
compared efﬁcacy between different DAPT regimens
(aspirin plus either ticagrelor in PLATO or prasugrel
in TRITON-TIMI 38, both versus clopidogrel plus
aspirin) and not the duration of DAPT following ACS.
Randomized studies comparing longer- versus
shorter-term DAPT after ACS are lacking. The present
trial showed a very low rate of thrombotic events
with newer-generation DES, even after ACS, in the
6-month DAPT group. However, with ACS, it seems
important to maintain an effective antiplatelet agent
between 6 and 12 months in aspirin responders. The
aim of long-term DAPT after ACS is to reduce not only
the risk of late ST but also the risk of recurrent spon-
taneous ischemic events. In previous trials analyzing
evolution after ACS (40), most thrombotic events
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Following deployment of new-generation DES, 6 and
24 months of DAPT are associated with similar rates of
thrombotic and bleeding events in patients who are
responsive to the platelet inhibitory effects of aspirin.
TRANSLATIONAL OUTLOOK: Future research
should seek to identify the speciﬁc clinical character-
istics associated with beneﬁt or harm related to
shorter or longer durations of DAPT following
deployment of various types of coronary stents.
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784occurred within the ﬁrst 6 months. In the present
trial, there was no signiﬁcant difference in throm-
botic event rate in ACS patients according to DAPT
duration.
ANTIPLATELET THERAPY MONITORING. There is no
doubt that long-course aspirin attenuates the risk of
MI, stroke, and vascular-related deaths in patients
with cardiovascular disease (23). The major contro-
versy about aspirin therapy is why certain patients
do not show beneﬁt with such therapy and how
they might be identiﬁed. Reanalyzing data reported
by the Aspirin Trialists’ Collaboration (23), with an
aspirin-resistance odds ratio factored in, the risk
reduction in aspirin-sensitive patients is likely to be
>50%, whereas in aspirin-resistant patients, risk
seems to noticeably increase (41–43). Several pro-
spective studies demonstrated an association be-
tween biochemical aspirin resistance and clinical
outcome (42–45). In these trials, aspirin resistance
was associated with increased risk of MI, stroke, or
cardiac death, and this was conﬁrmed by a large-scale
meta-analysis (24). Platelet response to aspirin, as
measured by collagen- and adenosine diphosphate–
induced light transmittance aggregometry, PFA-100,
and urinary thromboxane, is dose-related, indicating
that aspirin nonresponse decreases with increasing
dose from 75 to 325 mg (25). The recent randomized
ARCTIC (Assessment by a Double Randomization
of a Conventional Antiplatelet Strategy versus a
Monitoring-guided Strategy for Drug-Eluting Stent
Implantation and of Treatment Interruption versus
Continuation One Year after Stenting) trial of a
bedside platelet function test was neutral in its ﬁnd-
ings (46); however, only 27% of patients had ACS, and
in stable patients, no data supported prolonged DAPT
for new-generation DES.
Despite the variety of tests available, there is no
consensus as to the standard for measuring platelet
activation, and many deﬁnitions of aspirin resistance
depend on which test is used (25). The possibility of
using bedside assays to monitor aspirin offers an
opportunity to compare 2 strategies in good aspirin
responders: aspirin-clopidogrel (prasugrel or tica-
grelor) versus aspirin alone. In the ADAPT-DES
(Assessment of Dual Antiplatelet Therapy With
Drug-Eluting Stents) trial, investigators reported that
high platelet reactivity on aspirin was not signiﬁ-
cantly associated with ST, MI, or mortality after DES
implantation, but was an independent predictor of
freedom from clinically-relevant bleeding. However,
the trial was designed for ST occurrence; in-
vestigators did not compare DAPT duration and
aspirin efﬁcacy alone (47).Crossover from DAPT to single antiplatelet therapy
after 6 months is possible in good aspirin responders.
However, in the present aspirin-resistant group, the
rate of adverse events was also very low, probably
due to overtreatment of patients with known aspirin
resistance. The role of aspirin resistance monitoring
in clinical practice should be questioned.
STUDY LIMITATIONS AND STRENGTHS. Due to enroll-
ment difﬁculties, recruitment stopped at 2,031 pa-
tients, rather than the 2,475 patients required to have
900 analyzable patients in each group; however, as
we ﬁnally had an event rate of 1.5% (compared to the
3% expected), and as we are far from the boundary,
the sample size is enough for the conclusion to be
valid. The study was open-label and not placebo-
controlled in the 6-month arm. However, all clinical
endpoints were assessed by members of an inde-
pendent clinical event adjudication committee, and
statistical analyses were performed by independent
statisticians.
CONCLUSIONS
The ITALIC trial showed that bleeding and thrombotic
event rates were not signiﬁcantly different between
6- and 24-month DAPT groups after PCI with
second-generation DES, and that 6-month DAPT was
noninferior to 24-month DAPT in good aspirin
responders. Noninferiority was also observed in the
subgroup of unstable patients (one-half of patients).
Larger trials are needed to assess the effect of anti-
platelet duration in ACS patients.
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